Abstract
Purpose
Crohn’s disease (CD) is a refractory inflammatory bowel disease of unknown etiology, frequently complicated by malnutrition. It is thought that the delayed wound healing associated with this malnutrition in CD patients might adversely affect the therapeutic benefits of infliximab (IFX). Therefore, we investigated the effects of nutritional status on IFX treatment.
Methods
We assessed nutritional status and CD activity when IFX therapy was initiated and following the third dose, 6 weeks later. Nutritional status was assessed using the body mass index (BMI) and nutritional risk index (NRI), whereas CD activity was assessed using the CD activity index (CDAI).
Results
All patients with a BMI ≥ 18.5 kg/m2 at the time of IFX therapy met the effective criteria for the CDAI, and IFX treatment was considered responsive in these patients. Furthermore, IFX treatment was responsive, with a high level of effectiveness, in all five subjects (31.3 %) with NRI scores of 97.5 and above with no risk of malnutrition (p = 0.037).
Conclusions
Our results suggest that nutritional status does influence the therapeutic effect of IFX in CD patients. The response rate to IFX treatment thus could be improved by optimizing the nutritional status. We recommend comprehensive nutritional assessment and intervention prior to IFX treatment schedules.
Similar content being viewed by others
Abbreviations
- CD:
-
Crohn’s disease
- IFX:
-
Infliximab
- RCT:
-
Randomized controlled trial
- BMI:
-
Body mass index
- NRI:
-
Nutritional risk index
- CDAI:
-
Crohn’s disease activity index
- Alb:
-
Albumin
- CRP:
-
C-reactive protein
References
Alastair F, Emma G, Emma P. Nutrition in inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2011;35(5):571–80.
Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641–57.
Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2003;(4):CD003574.
) Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;(1):CD006893.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–85.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet. 2002;359(9317):1541–9.
Rutgeerts P, Faegan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126:402–13.
Targan SR, Hanauer SB, van Deventer SJ, Mayyer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha gor Crohn’s disease. N Engl J Med. 1997;337:1029–35.
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–405.
Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, et al. Baseline tumor necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:1208–15.
Tomita K, Chiba T, Sugai T, Habano W. Association between tumor necrosis factor-alpha and Fc-gamma receptor polymorphisms with infliximab in Crohn’s disease. Hepatogastroenterology. 2010;57:535–9.
Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. Gastroenterolgy. 1976;70:439–44.
Buzy GP, Knox L, Crosby LO, Eisenberg JM, Haakenson CM, McNeal GD, et al. Study protocol: a randomized clinical trial of total parenteral nutrition in malnourished surgical patients. Am J Clin Nutr. 1988;47:366–81.
Nezu R, Takagi Y, Ito T, Matsuda H, Okada A. The importance of total parenteral nutrition-associated tissue zinc distribution in wound healing. Surg Today. 1999;29:34–41.
Collins N. Protein-energy malnutrition and involuntary weight loss: nutritional and pharmacological strategies to enhance wound healing. Expert Opin Pharmacother. 2003;4:1121–40.
Houeing RH, Rozendaal M, Wouters-Wesseling W, Beulens JW, Buskens E, Haalboom JR. A randomized, double-blind assessment of the effect of nutritional supplementation on the prevention of pressure ulcers in hip-fracture patients. Clin Nutr. 2003;22:401–5.
Bozzetti F. Rationale and indications for preoperative feeding of malnourished surgical cancer patients. Nutrition. 2002;18:953–9.
Maeda K, Nagahara H, Shibutani M, Otani H, Sakurai K, Toyokawa T, et al. A preoperative low nutritional prognostic index correlates with the incidence of incisional surgical site infections after bowel resection in patients with Crohn’s disease. Surg Today. 2014 [Epub ahead of print].
Shinkawa H, Takemura S, Uenishi T, Sakae M, Ohata K, Urata Y, et al. Nutritional risk index as an independent predictive factor for the development of surgical site infection after pancreaticoduodenectomy. Surg Today. 2013;43:276–83.
Colombel J.F, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.
Van Assche G, Magdelaine-Beuzelin C, D’Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134(7):1861–8.
ASPEN Board of Directors and the Clinical Guidelines Task Force: guidelines for use of parenteral and enteral nutrition in adult and pediatric patients. JPEN. 2002;26(Suppl 1).
Hanauer SB, Sandborn W. Practice Parameters Committee of the American College of Gastroenterology: management of Crohn’s disease in adults. Am J Gastorenterol. 2001;96:635–43.
Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, et al. European Crohn’s and Colitis Organisation: European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut. 2006;55(Suppl 1):i16–35.
Okada M, Uao T, Yamamoto T, Takenaka K, Imamura K, Maeda K, et al. Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn’s disease. Hepatogastroenterology. 1990;37:72–80.
Rigaud D, Angel LA, Cerf M, Carduner MJ, Melchior JC, Sautier C, et al. Mechanisms of decreased food intake during weight loss in adult Crohn’s disease patients without obvious malabsorption. Am J Clin Nutr. 1994;60(5):775–81.
Mamoru W. Crohn’s disease treatment guidelines. Health and Labour Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan (in Japanese). 2011:47.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that no competing interests exist.
Rights and permissions
About this article
Cite this article
Sumi, R., Nakajima, K., Iijima, H. et al. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn’s disease. Surg Today 46, 922–929 (2016). https://doi.org/10.1007/s00595-015-1257-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-015-1257-5